- Oops!Something went wrong.Please try again later.
Neuronetics Inc (NASDAQ: STIM) has announced that a peer-reviewed paper showed significantly lower seizure risk with NeuroStar Advanced Therapy for Mental Health than with TMS treatments that claim deeper stimulation with H-Coil technology.
The journal surveyed approximately 500 members of the Clinical TMS Society (CTMSS) about seizures in their practice.
A total of 125 surveys were evaluated, which included 586,656 TMS treatment sessions.
"While the overall occurrence of seizures with all TMS treatments is low, this study showed that the real-world risk for seizure was 52 to 90 times higher with H-coil TMS treatment than with NeuroStar treatment," stated Cory Anderson, VP, Clinical Affairs & Interim VP, R&D, Neuronetics.
NeuroStar, an advanced therapy system, is a transcranial magnetic stimulation (TMS) treatment for major depressive disorder in adults, with over four million treatments delivered.
Price Action: STIM stock is down 2.61% at $6.35 during the market session on the last check Tuesday.
See more from Benzinga
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.